Assistance Publique–Hôpitaux de Paris

One Biosciences Partners With AP-HP to Launch a Single-cell Research Project on a Rare Kidney Disease

Retrieved on: 
Friday, November 10, 2023
Research, Assistance Publique–Hôpitaux de Paris, Transplant, AP-HP, Kidney disease, Disease, AI, A.I, Patient, Medicine, Creative Biolabs, Heart, Partnership, Syndrome, Biomarker, Sorbonne University, Hospital, Silla, Curie Institute (Paris), Single-cell analysis, Pharmaceutical industry, News

PARIS, Nov. 10, 2023 (GLOBE NEWSWIRE) -- One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I.

Key Points: 
  • PARIS, Nov. 10, 2023 (GLOBE NEWSWIRE) -- One Biosciences, a biotech company leveraging the power of single-cell analysis and A.I.
  • A condition characterized by a gradual loss of kidney function over time, this particular disease has no viable therapeutic option to date and transplantation is often the only alternative, despite frequent relapses.
  • One Biosciences will leverage the data to identify new therapeutic targets in this rare kidney disease in order to develop precision medicines and biomarkers of a relapse of the disease via its discovery platform.
  • This is an important milestone, and I'd like to thank our partners for their commitment," said Hedi Ben Brahim, CEO of One Biosciences.

X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

Retrieved on: 
Tuesday, August 8, 2023
University, Interim, Assistance Publique–Hôpitaux de Paris, Drug development, Roche, Therapy, WHIM, Harvard University, Salk Institute for Biological Studies, Biogen, Hospital, MBA, Research, CMO, Doctor of Philosophy, Merck & Co., Rutgers University, Pierre and Marie Curie University, X4, Boehringer Ingelheim, MD, Patient, WHIM syndrome, Immune system, Growth, Rare, Pharmaceutical industry, Ligand Pharmaceuticals

“We are thrilled to welcome Christophe to our leadership team at this exciting time at X4,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.

Key Points: 
  • “We are thrilled to welcome Christophe to our leadership team at this exciting time at X4,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
  • We would also like to thank Dr. Murray Stewart, who has been serving as our Interim Chief Medical Officer, for his exceptional contributions and his leadership.
  • The company has made great progress and I look forward to adding to its continued forward momentum.
  • He received his MD and PhD in internal medicine/endocrinology-metabolism from the University of Paris, France, and completed his MBA at Rutgers University.

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

Retrieved on: 
Thursday, May 11, 2023
Graft-versus-host disease, TRAC, Euronext Growth, Assistance Publique–Hôpitaux de Paris, CD19, European Hematology Association, Relapse, CD52, Cyclophosphamide, FC, Allotransplantation, CAR, Patient, B-ALL, Risk, EHA, Alemtuzumab, FCA, Infrared spectroscopy correlation table, Safety, Vaccine, Pharmaceutical industry, Cellectis

“Cellectis is excited to present updated clinical and translational data from its BALLI-01 clinical trial (evaluating UCART22) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Key Points: 
  • “Cellectis is excited to present updated clinical and translational data from its BALLI-01 clinical trial (evaluating UCART22) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
  • The data show that UCART22 was well tolerated and clinical responses were achieved.
  • UCART22 continues to have a good safety profile, with no serious treatment emergent adverse events (TEAEs) or DLTs reported.
  • Overall, these data support the safety and preliminary efficacy of UCART22 in a heavily pretreated r/r B-ALL population.

Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study

Retrieved on: 
Tuesday, March 14, 2023
ISR, Patient, FDA, Bias, SFA, Assistance Publique–Hôpitaux de Paris, Coronary artery disease, BTK, De novo, DEB, CE marking, IDE, TVF, Pharmaceutical industry

GENEVA, March 14, 2023 /PRNewswire/ -- MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study.

Key Points: 
  • GENEVA, March 14, 2023 /PRNewswire/ -- MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study.
  • SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon [DEB SELUTION], versus a limus drug-eluting stent [DES].
  • SELUTION DeNovo is the largest DEB study ever initiated, involving up to 70 participating sites across 15 countries.
  • This will complement the substantial experience that the company has gained with the SELUTION DeNovo trial in Europe.

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Pharmaceutical, Health, Cardiology, University, Hospital, IRB, Alteplase, AP, Type, University Hospitals Birmingham NHS Foundation Trust, Agence nationale de sécurité du médicament et des produits de santé, Partnership, Marketing, Assistance Publique–Hôpitaux de Paris, Stroke, Infarction, ISIN, RHU, Biologics license application, European Medicines Agency, Death, Quality of life, Pulmonary embolism, BLA, EVT, Sri Jayadeva Institute of Cardiovascular Sciences and Research, TNK, EMA, Agence nationale de la recherche, FDA, MRS, Disability, Tenecteplase, IRAS, Șaeș, Reperfusion, Standard of care, Safety, IPO, Modified Rankin Scale, Patient, Thrombectomy, Myocardial infarction, GREEN, Pharmaceutical industry, Medical imaging

ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.

Key Points: 
  • ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.
  • We have fully met our patient enrollment goals in 2022 and are involving new countries and hospitals in 2023.
  • We look forward to continuing the clinical development of glenzocimab in the treatment of myocardial infarction in partnership with the University of Birmingham (UK).
  • The recognition of this pivotal study design supports a future application for marketing authorization for glenzocimab in stroke in Europe.

Covid - 19: Laboratoire Cerba Detects First Case of Omicron Variant in Mainland France

Retrieved on: 
Thursday, December 2, 2021
Biotechnology, Managed Care, Other Health, Health, General Health, State, Local, Pharmaceutical, Medical Devices, Infectious Diseases, Hospitals, Public Policy, Government, CEO, Endocrinology, National Healthcare Group, Sertraline, Diagnosis, Health, General Directorate for Internal Security, Severe acute respiratory syndrome coronavirus 2, Vaccine, Epidemiology, Omicron, Charles de Gaulle Airport, Genetics, Lists of diseases, Risk, SARS, Public policy, Roissy, Public health, Medicine, Assistance Publique–Hôpitaux de Paris, Certification, Pharmaceutical industry, Medical imaging, laboratoire Cerba, Cerba HealthCare, LABORATOIRE CERBA, CERBA HEALTHCARE

Laboratoire Cerba, a global leader in specialized clinical pathology and member of the Cerba HealthCare Group, has detected a case of the Omicron variant from the sample of a patient arriving from Nigeria who was tested at Roissy Charles De Gaulle airport.

Key Points: 
  • Laboratoire Cerba, a global leader in specialized clinical pathology and member of the Cerba HealthCare Group, has detected a case of the Omicron variant from the sample of a patient arriving from Nigeria who was tested at Roissy Charles De Gaulle airport.
  • The authorities - Sant Publique France [Public Health France], Agence Rgionale de Sant Ile de France [Paris Regional Health Agency] and Direction Gnrale de Sant [General Directorate for Health]- were immediately informed.
  • Laboratoire Cerba, chosen last October by the French Health Authorities to participate in the Emergen consortium, carries out between 1,000 and 1,500 sequencings per week with results returned in less than 5 days.
  • Cerba HealthCare, a leading player in medical diagnosis, aims to support the evolution of health systems towards more prevention.

MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013

Retrieved on: 
Wednesday, December 1, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Patient, Euronext Paris, CEO, European Medicines Agency, Biomarker, Head, EAP, US Food Sovereignty Alliance, Special access program, MD, Cancer, Assistance Publique–Hôpitaux de Paris, GI, Professor, Orphan, EST, Survival, EMA, ASH, Society, Hospital, Sorbonne University, FDA, Webcast, Immune system, Graft-versus-host disease, Food, CGMP, Pharmaceutical industry, MaaT013, MaaT Pharma, MAAT013, MAAT PHARMA

MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key Points: 
  • MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
  • MaaT013 was investigated in a Phase 2 clinical trial (HERACLES, NCT03359980 ) and is being administered in an early access program in France.
  • MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology.
  • MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021

Retrieved on: 
Thursday, September 9, 2021

The event will highlight the GRANITE (individualized neoantigen immunotherapy) Phase 1/2 data in advanced solid tumors which is being presented during a mini- oral presentation at ESMO 2021, in addition to data from the SLATE v1 shared neoantigen immunotherapy program in KRAS mutant advanced solid tumors.

Key Points: 
  • The event will highlight the GRANITE (individualized neoantigen immunotherapy) Phase 1/2 data in advanced solid tumors which is being presented during a mini- oral presentation at ESMO 2021, in addition to data from the SLATE v1 shared neoantigen immunotherapy program in KRAS mutant advanced solid tumors.
  • The call and accompanying slides will be webcast live on the Events page under the Investors & Media section of the companys website at www.gritstone.com .
  • Daniel Catenacci, M.D., is an associate professor of medicine and director of the gastrointestinal oncology program at the University of Chicago.
  • Additionally, Dr. Catenacci designs and executes novel clinical trials to implement treatment strategies based on these laboratory and clinical discoveries.

Crosscope Inc. and AP-HP Greater Paris University Hospitals reach a multi-year collaboration agreement for AI-powered liver cancer detection

Retrieved on: 
Wednesday, June 16, 2021
Health care, Medicine, Assistance Publique–Hôpitaux de Paris, University Hospitals Cleveland Medical Center, Health, Biopsy, Liver

Microscopic examination of liver biopsies remains a very challenging task and the gold standard for diagnosing and staging of cancer.

Key Points: 
  • Microscopic examination of liver biopsies remains a very challenging task and the gold standard for diagnosing and staging of cancer.
  • We continue to expand our portfolio of AI modules for additional tissue types with this collaboration focusing on liver biopsies."
  • About Assistance Publique - Hpitaux de Paris / Greater Paris University Hospitals - The leading hospital and university centre (CHU) in Europe, Greater Paris University Hospitals and its 39 hospitalsare organised into six hospital-university groups (AP-HP.
  • In 2015, Greater Paris University Hospitals also founded the Greater Paris University Hospitals Research Foundation to support the biomedical and health research performed in all its hospitals.

Dassault Systèmes Simulates Airflow in Paris Hospital to Reduce Risks of Exposure to COVID-19

Retrieved on: 
Tuesday, March 23, 2021
Software, General Health, Health, Electronic design automation, Data management, Hospitals, Technology, Other Technology, Companies, Dassault Group, CAC 40, Dassault Systèmes, Societates Europaeae, Economy of France, DSY, Simulia, Simulation, Assistance Publique–Hôpitaux de Paris

Dassault Systmes (Euronext Paris: #13065, DSY.PA) (Paris:DSY) is helping the Piti-Salptrire hospital in Paris part of AP-HP, Europes largest university hospital system evaluate the risks of coronavirus infection during the COVID-19 pandemic by using airflow simulation technology.

Key Points: 
  • Dassault Systmes (Euronext Paris: #13065, DSY.PA) (Paris:DSY) is helping the Piti-Salptrire hospital in Paris part of AP-HP, Europes largest university hospital system evaluate the risks of coronavirus infection during the COVID-19 pandemic by using airflow simulation technology.
  • AP-HP is relying on Dassault Systmes 3D simulation solutions to reinforce its existing hospital safety measures for reducing exposure risks in both patient care and workplace environments.
  • When France entered its second nationwide lockdown in October 2020, Dassault Systmes simulation engineers collaborated with hospital teams and the Paris architect Arnaud Delloye.
  • Dassault Systmes SIMULIA simulation software was used to model and analyze the airflow as well as the deposits of droplets in the room.